Artrya Advances Toward FDA Approval

Artrya Limited (AU:AYA) has released an update.

Artrya Limited, an Australian AI healthcare company, has progressed its efforts to gain FDA approval by submitting a second Q-Submission to finalize its 510(k) application for its AI platform targeting coronary artery disease. The company anticipates a meeting with the FDA within the next four to six weeks to confirm their approach, with the goal of obtaining regulatory clearance later in the year.

For further insights into AU:AYA stock, check out TipRanks’ Stock Analysis page.